![shutterstock_1979232446 (1)](https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/05/shutterstock_1979232446-1.jpg)
What We Do
Pipeline
Oncology Focused Pipeline
The core value of OBI lies in its passion to develop and deliver a portfolio of unique antibody-drug conjugates (ADCs) drugs for patients, in addition to its promising Globo H active immunotherapy. This evolving portfolio includes a spectrum of cancer targets, such as TROP2, Nectin-4, HER2, and other potential targets.
This table provides an overview of our pipeline.
Molecule Name
Target
Potential Indications
Status
Modality
Molecule Name
Adagloxad simolenin
Target:
Globo H
Potential Indications:
Breast (TNBC)
Status:
Phase 3
Modality:
Active Immunotherapy
Molecule Name
OBI-833
Target:
Globo H
Potential Indications:
Lung (NSCLC)
Status:
Phase 2
Modality:
Active Immunotherapy
Molecule Name
OBI-3424
Target:
AKR1C3
Potential Indications:
Liver (HCC) and T-ALL
Status:
Phase 2
Modality:
Prodrug
Molecule Name
OBI-992
Target:
TROP2
Potential Indications:
Solid Tumors
Status:
Phase 1
Modality:
ADC
Molecule Name
OBI-902
Target:
TROP2
Potential Indications:
Solid Tumors
Status:
Preclinical
Modality:
ADC
Molecule Name
OBI-904
Target:
Nectin-4
Potential Indications:
Solid Tumors
Status:
Preclinical
Modality:
ADC
Molecule Name
BsADC
Target:
TROP2, HER2
Potential Indications:
Solid tumors
Status:
Discovery
Modality:
BsADC